search icon
      blog search icon

      APTX Witnesses Remarkable Recovery Amidst Challenges

      By Wasim Omar

      Published on

      May 19, 2023

      7:43 AM UTC

      APTX Witnesses Remarkable Recovery Amidst Challenges

      Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company specializing in brain and nervous system disorder treatments, is experiencing an astonishing after-market price surge.

      Despite a challenging day, the stock is making an epic recovery, soaring by an impressive 21% after hours. This unexpected jump is capturing attention and raising speculation about the factors driving Aptinyx Inc.’s remarkable after-market performance.

      Not all Hope is Lost for Aptinyx

      Aptinyx Inc. (APTX) faced a sell-off during the day, amid dissolution scares, dropping from $0.10 to $0.06. However, after hours, the stock experienced a significant rebound as bullish investors drove it back up to nearly $0.08.

      While the future remains uncertain, there are possibilities of a business combination or exploring alternative options instead of dissolution. With available funds and multiple scenarios on the table, APTX’s situation continues to be dynamic, attracting attention from investors seeking potential opportunities.

      APTX Milestone Challenges

      Aptinyx, earlier this year, faced challenges in its milestone update. The Phase 2b clinical study of NYX-783 for post-traumatic stress disorder (PTSD) did not show enough improvement to continue the program.

      Aptinyx engaged Ladenburg Thalmann as an advisor for strategic alternatives and implemented workforce reduction to cut costs. Another study with NYX-458 for cognitive impairment associated with Parkinson’s disease did not demonstrate meaningful improvements.

      However, the company is still pursuing the development of NYX-783 as a treatment for opioid use disorder (OUD), with ongoing research collaboration and funding from the National Institutes of Health (NIH).


      The surge in the price of APTX is nothing short of remarkable. While uncertainties loom, Aptinyx remains resilient, exploring potential business combinations and alternatives.

      Despite setbacks, the company continues its pursuit of developing NYX-783 for opioid use disorder, supported by research collaboration and funding from the National Institutes of Health (NIH). Investors are closely watching APTX for potential opportunities amidst its dynamic situation.

      More From Stocks telegraph